Trial Profile
Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Fatty liver; Hepatic fibrosis
- Focus Therapeutic Use
- Acronyms STHENIC
- 16 Jul 2019 New trial record
- 11 Jun 2019 Primary end point (The change of hepatic steatosis between SGLT-2 inhibitors group(Additional treatment with SGLT-2 inhibitor) and control group (aggressive conventional treatment without SGLT-2 inhibitors) at 24 weeks after starting this trial.) has been met, as per results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association